hypertension - angiotensin-receptor blockers - all diseases requiring ACEi (HF, CHD, HT,...) clinical trials results meta-analysis

<h1> <a href="TM7-4-angiotensin-receptor blockers-hypertension" > <strong>hypertension</strong> - angiotensin-receptor blockers </a> - all diseases requiring ACEi (HF, CHD, HT,...) trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="../TRC_t7954.htm"> ELITE, 1997 </a> <br> </td> <td> Losartan<br>  <i>versus</i> <br> Captopril </td> <td> </td> <td> follow-up 1 y<br> n=352/370<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t7955.htm"> ELITE-II, 2000 </a> <br> </td> <td> Losartan<br>  <i>versus</i> <br> Captopril </td> <td> </td> <td> follow-up 1.5 y<br> n=1578/1574<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t7956.htm"> OPTIMAAL, 2001 </a> <br> </td> <td> Losartan<br>  <i>versus</i> <br> Captopril </td> <td> </td> <td> follow-up 2.7 y<br> n=2744/2733<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t7957.htm"> VALIANT/Val, 2003 </a> <br> </td> <td> Valsartan<br>  <i>versus</i> <br> Captopril </td> <td> </td> <td> follow-up 2.1 y<br> n=4909/4909<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t7958.htm"> VALIANT/Val+Cap, 2003 </a> <br> </td> <td> Valsartan<br>  <i>versus</i> <br> Captopril </td> <td> </td> <td> follow-up 2.1 y<br> n=4885/4909<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t7959.htm"> ONTARGET/Tel, 2008 </a> <br> </td> <td> Telmisartan<br>  <i>versus</i> <br> Ramipril </td> <td> </td> <td> follow-up 4.7 y<br> n=8542/8576<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t7960.htm"> ONTARGET/Tel+Ram, 2008 </a> <br> </td> <td> Telmisartan<br>  <i>versus</i> <br> Ramipril </td> <td> </td> <td> follow-up 4.7 y<br> n=8502/8576<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t7961.htm"> DETAIL, 2004 </a> <br> </td> <td> Telmisartan<br>  <i>versus</i> <br> Enalapril </td> <td> </td> <td> follow-up 5 y<br> n=120/130<br> <br> <br> </td> </tr> <tr> <td> <a href="../TRC_t9535.htm"> Jikei Heart, 2007 </a> <br> NCT00133328 </td> <td> valsartan (40-160 mg per day<br>  <i>versus</i> <br> conventional cardiovascular treatment without angiotensin receptor blockers </td> <td> Japanese patients who were undergoing conventional treatment for hypertension, coronary heart disease, heart failure, or a combination of these disorders </td> <td> follow-up 3.1 years<br> n=-9/-9<br> Parallel groups<br> open <br> </td> </tr> </table> <h2>References</h2> <p> <b>HIJ-CREATE, 0 : </b> Kasanuki H, Hagiwara N, Hosoda S, Sumiyoshi T, Honda T, Haze K, Nagashima M, Yamaguchi J, Origasa H, Urashima M, Ogawa HAngiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). <i>Eur Heart J 2009;30:1203-12</i> [PMID 19346521] 10.1093/eurheartj/ehp101 </p> <p> <b>ELITE, 1997 : </b> Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PIRandomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) <i>Lancet 1997;349:747-52</i> [PMID 9074572] </p> <p> <b>ELITE-II, 2000 : </b> Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan BEffect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. <i>Lancet 2000;355:1582-7</i> [PMID 10821361] </p> <p> <b>OPTIMAAL, 2001 : </b> Dickstein K, Kjekshus JEffects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. <i>Lancet 2002;360:752-60</i> [PMID 12241832] </p> <p> <b>VALIANT/Val, 2003 : </b> Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RMValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. <i>N Engl J Med 2003;349:1893-906</i> [PMID 14610160] </p> <p> <b>VALIANT/Val, 2003 : </b> McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer MThe effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>J Am Coll Cardiol 2006;47:726-33</i> [PMID 16487836] </p> <p> <b>VALIANT/Val+Cap, 2003 : </b> Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Køber L, Maggioni AP, Solomon SD, Swedberg K, Van de Werf F, White H, Leimberger JD, Henis M, Edwards S, Zelenkofske S, Sellers MA, Califf RMValsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. <i>N Engl J Med 2003;349:1893-906</i> [PMID 14610160] </p> <p> <b>VALIANT/Val+Cap, 2003 : </b> McMurray J, Solomon S, Pieper K, Reed S, Rouleau J, Velazquez E, White H, Howlett J, Swedberg K, Maggioni A, Køber L, Van de Werf F, Califf R, Pfeffer MThe effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). <i>J Am Coll Cardiol 2006;47:726-33</i> [PMID 16487836] </p> <p> <b>ONTARGET/Tel, 2008 : </b> Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson CTelmisartan, ramipril, or both in patients at high risk for vascular events. <i>N Engl J Med 2008;358:1547-59</i> [PMID 18378520] </p> <p> <b>ONTARGET/Tel, 2008 : </b> Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfield J, Teo K, Yusuf SEffects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. <i>Circulation 2009;120:1380-9</i> [PMID 19770395] </p> <p> <b>ONTARGET/Tel+Ram, 2008 : </b> Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson CTelmisartan, ramipril, or both in patients at high risk for vascular events. <i>N Engl J Med 2008;358:1547-59</i> [PMID 18378520] </p> <p> <b>ONTARGET/Tel+Ram, 2008 : </b> Verdecchia P, Sleight P, Mancia G, Fagard R, Trimarco B, Schmieder RE, Kim JH, Jennings G, Jansky P, Chen JH, Liu L, Gao P, Probstfield J, Teo K, Yusuf SEffects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. <i>Circulation 2009;120:1380-9</i> [PMID 19770395] </p> <p> <b>DETAIL, 2004 : </b> Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen JAngiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. <i>N Engl J Med 2004;351:1952-61</i> [PMID 15516696] </p> <p> <b>Jikei Heart, 2007 : </b> Mochizuki S, Dahlöf B, Shimizu M, Ikewaki K, Yoshikawa M, Taniguchi I, Ohta M, Yamada T, Ogawa K, Kanae K, Kawai M, Seki S, Okazaki F, Taniguchi M, Yoshida S, Tajima NValsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. <i>Lancet 2007;369:1431-9</i> [PMID 17467513] </p>